THW News and Press, Tekla World Healthcare Fund Shares of Beneficial Interest From 11/14/19

For quite some time now, I have suggested that every investor maintain some type of exposure to the healthcare industry. There are a few reasons for this including the industry's generally defensive nature and the considerable growth potential that it boasts. There are a number of ways to inve...

Author's Note : This article was originally released to members on October 2, 2019. 3 More Quick Rotation Opportunities Rotating between overvalued closed-end funds into less overvalued ones is a cornerstone strategy at CEF/ETF Income Laboratory which we call "compounding income on st...

Co-produced by Stanford Chemist . This article was originally published on October 13th, 2019. We recently dived into the benefits of capital gains in distributions, so it felt like an appropriate time to illustrate the often misunderstood return of capital (ROC). This is a commonly deb...

The Institute for Clinical and Economic Review (ICER), a Boston-based nonpartisan nonprofit with no policy-making role, has emerged as a major influencer on pricing by drugmakers. More news on: Sanofi, Regeneron Pharmaceuticals, Inc., Amgen Inc., Healthcare stocks news, News on ETFs, ...

Presidential candidate Senator Elizabeth Warren (D-MA) has finally released the projected cost of her plan for universal healthcare, called "Medicare for All," a whopping $20.5T over 10 years. More news on: Tekla World Healthcare Fund, BlackRock Health Sciences Trust, The Gabelli Healthc...

In a statement , the FDA says chronic shortages of certain medicines in the U.S. have not produced the expected responses from drugmakers that traditional economics predict, specifically, increasing prices to reflect a supply/demand imbalance aimed at achieving profitable production to sati...

In the face of criticism from her Presidential rivals, Senator Elizabeth Warren (D-MA) says she will "soon release" her plan to pay for "Medicare for All," her proposal for universal healthcare in the U.S. She commented on the issue during a campaign stop in Indianola, IA. More news on: ...

On a strict party line basis, the U.S. House of Representatives' Education and Labor Committee voted 27-21 backing Speaker Nancy Pelosi's drug pricing bill (H.R. 3). All 27 Dems voted in favor and all 21 GOP members voted against. More news on: Pfizer Inc., Merck & Co., Inc., Bristol...

A preliminary analysis from the nonpartisan Congressional Budget Office (CBO) found that House Speaker Nancy Pelosi's (D-CA 12th District) bill to lower drug prices would save Medicare $345B between 2023 and 2029 by allowing the Secretary of Health and Human Services to negotiated lower pr...

According to a new report from the nonprofit Institute for Clinical and Economic Review (ICER), AbbVie ( ABBV -0.6% ) and Roche ( OTCQX:RHHBY -1.6% ) were number one and two, respectively, in terms of the impact of their price increases on U.S. drug spending. More news on: AbbVie Inc...